CA
NZ
UK
AU
IND
US
• OS Therapies (OSTX) is an oncology-focused biotechnology company that has attracted renewed attention amid broader interest in small-cap clinical-stage names.
• Erasca (NASDAQ: ERAS) is a clinical-stage precision oncology company focused on therapies aimed at the RAS/MAPK pathway in cancer.
• Zentalis Pharmaceuticals (NASDAQ: ZNTL) has attracted renewed attention as a clinical-stage oncology company.
• REGENXBIO (NASDAQ: RGNX) is a clinical and platform-focused gene therapy company that has drawn renewed market interest.
• Prelude Therapeutics has drawn renewed market interest amid a broader rotation back toward oncology biotech.
• The company is a clinical-stage biotech working on therapies based on CRISPR gene-editing technology.
• Aldeyra Therapeutics (NASDAQ: ALDX) has drawn renewed market interest amid attention on its ophthalmology-focused pipeline.
• Alector (NASDAQ: ALEC) has drawn renewed market interest amid attention on neurodegeneration research.
• Acumen Pharmaceuticals (NASDAQ: ABOS) has drawn renewed market interest as Alzheimer’s research returns to focus.
• Vor Biopharma (NASDAQ: VOR) has seen a sharp move, reviving discussion about speculative interest in cell-therapy biotech.
Please wait processing your request...